Why Zymeworks Stock Is Crashing Today
Shares of Zymeworks (NYSE: ZYME) are crashing today, down by 23.7% as of 11:20 a.m. EST, after the company announced data late on Wednesday from the dose-escalation portion of a phase 1 study evaluating antibody-drug conjugate ZW49 in treating several types of HER2‑positive cancer.
Zymeworks stated that there were "multiple confirmed responses and stable disease observed in several tumor types" in patients treated with ZW49. The company also said that the safety profile for the experimental therapy looked pretty good. While there were some adverse events, 90% of them were mild or moderate in severity.
Image source: Getty Images.
Source Fool.com
